Fluoxetine and Fentanyl: Interaction Details
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Fluoxetine and Fentanyl interaction:
Fentanyl
- Abstral
- Actiq
- Fentora
- Onsolis
- Subsys
- Ionsys
Fluoxetine
- Prozac
- Prozac Weekly
- Rapiflux
- Sarafem
- Selfemra
What Happens When You Take Fluoxetine With Fentanyl
What can happen when they are taken together (rated Major)
Increased fentaNYL exposure and an increased risk of
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Taking fentaNYL together with a that also has activity may result in serotonin syndrome, and it may raise fentaNYL exposure, which can intensify or extend adverse events. symptoms usually appear within several hours to a few days after the drugs are started together, though they can emerge later.
When co-administration cannot be avoided, a lower fentaNYL dose should be considered until drug effects have stabilized, and patients should be checked often for and . Once a CYP3A4 inhibitor is stopped, its effect wanes and fentaNYL exposure falls.
This can lead to diminished , or to a withdrawal syndrome in patients who have become physically dependent on fentaNYL. If the CYP3A4 inhibitor is discontinued, consider raising the fentaNYL dose until effects are stable, and watch for signs of opioid withdrawal.234
Patients should also be observed for symptoms of serotonin syndrome, which can be life-threatening. Should it occur, stop the agents responsible and give supportive care and any other needed treatment.1
The Fluoxetine and Fentanyl Interaction, Explained
Taking fentanyl with fluoxetine (Prozac) can raise fentanyl levels in your body and also raise the risk of a serious reaction called . Fluoxetine can slow the way your body breaks down fentanyl, so the pain medicine can build up. That may mean stronger drowsiness and slowed breathing. Both drugs also boost , which can cause agitation, fast heartbeat, sweating, shaking, muscle twitching, or fever.
Serotonin symptoms usually show up within hours to a few days, but can appear later. Please don't stop or change either medicine on your own. Your pharmacist or doctor can adjust the fentanyl dose and check on you more often. Seek urgent help if you notice these warning signs.
Mechanism: fluoxetine (and norfluoxetine) inhibits -mediated fentanyl , increasing fentanyl exposure, plus (fentanyl has serotonergic activity). Evidence: established. Severity: major. Onset: unspecified; toxicity typically within hours to days, but may be delayed.
- Risks: , and increased or prolonged adverse effects including and .
- If is necessary: consider fentanyl dose reduction until stable effects are achieved; monitor frequently for respiratory depression, sedation, and serotonin toxicity.
- On discontinuing the : fentanyl exposure falls, with risk of reduced or withdrawal in dependent patients; consider increasing the fentanyl dose and monitor for withdrawal. Note fluoxetine's long means offset is gradual.
- If serotonin syndrome develops, discontinue the offending agents and provide supportive care.
See the 11 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Fluoxetine and Fentanyl Interact
The likely mechanism
of -mediated of fentaNYL;
How to Manage the Fluoxetine and Fentanyl Interaction
Your care team can usually manage this by tailoring your treatment. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise.
- Your fentanyl dose may need to be lowered and individualized until your response is stable, and your team may monitor you more closely for sleepiness and slowed breathing.
- Watch for symptoms such as agitation, sweating, tremor, muscle twitching, fast heartbeat, or fever, and get urgent help if they occur.
- If fluoxetine is ever stopped or changed, tell your team, since fentanyl levels may drop and the fentanyl dose may need adjusting. They will watch for withdrawal signs.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Fluoxetine or Fentanyl need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
9 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
The serotonin syndrome
presents with neuromuscular abnormalities (eg, hyperreflexia, tremor, muscle rigidity, clonus, peripheral hypertonicity, shivering), autonomic hyperactivity (eg, , mydriasis, diaphoresis, audible bowel sounds, diarrhea), and altered mental status (eg, agitation, delirium). The condition can be life-threatening.1
-
Report 2 · Study title
Case scenario: opioid association with serotonin syndrome: implications to the practitioners
A case report describes -associated in a 58-year-old man with chronic back pain. He had been stable on treatment for pain and depression, with a regimen of transdermal fentaNYL 75 mcg/hr patches, oxyCODONE 5 mg/acetaminophen 325 mg twice daily, celecoxib 200 mg twice daily, citalopram 40 mg once daily, and mirtazapine 50 mg at night.
He also took doxazosin 4 mg daily and zolpidem 12.5 mg as needed for insomnia. Because he reported inadequate pain control, fentaNYL was changed so that the patch was replaced every 2 days instead of every 3 days.
About 1 week after this fentaNYL increase, he reported anxiety, tremulousness, fever, and sweating. CloNIDine 0.2 mg every 4 hours was started, with no improvement in symptoms.
Symptoms persisted, and the next day haloperidol and LORazepam were given for anxiety and agitation. He stopped his fentaNYL patch and, 2 days later, presented to the emergency room with opiate withdrawal.
He was then diagnosed with serotonin syndrome even though the fentaNYL patch had been discontinued for 30 hours. Haloperidol, fentaNYL, oxyCODONE/acetaminophen, citalopram, and mirtazapine were stopped immediately, and symptoms resolved completely by the following day. Morphine sulfate was prescribed in place of fentaNYL, and citalopram and mirtazapine were restarted, with no recurrence of serotoninergic symptoms at follow-up.5
-
Report 3 · Study title
Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy
linked to fentaNYL use during an esophagogastroduodenoscopy was reported in a 39-year-old woman who also took sertraline 100 mg daily as an outpatient. She initially presented with hematemesis and had a history of alcoholic cirrhosis.
Before the esophagogastroduodenoscopy, an octreotide and pantoprazole drip was begun, and 2 doses of fentaNYL 50 micrograms and 2 doses of midazolam 1 mg were given. After the procedure she became somnolent and extremely rigid in all four extremities, and vecuronium and etomidate were given for immediate intubation.
The rigidity progressed, accompanied by diffuse diaphoresis, horizontal roving eye movements, and a fever of 105 degrees F. Because of the possibility of seizure activity, LORazepam 2 mg IV was given without improvement, and a propofol drip was started for continued during intubation.
A CPK of 2800 units/L and an ammonia level of 340 micromols/L indicated . A CT scan of the brain excluded an acute intracranial process, and the neurology team diagnosed serotonin syndrome resulting from an interaction between fentaNYL and sertraline.
Propofol was continued for sedation, and supportive treatment consisted of a cooling blanket and cyproheptadine. After 3 days her temperature and CPK normalized, and she was later extubated without further complications.6
-
Report 4 · Study title
Serotonin syndrome precipitated by fentanyl during procedural sedation
after IV fentaNYL administration during surgical procedures was reported in 2 patients who were also taking (sertraline and escitalopram). The first patient received IV fentaNYL (50 micrograms), midazolam (2 mg), and 2 doses of propofol (60 mg and 40 mg) at an outpatient surgery center before a carpal tunnel release.
Postoperatively she began shivering and grew increasingly agitated, and she was transferred to the emergency department. On presentation she was combative, diaphoretic, confused, unable to follow commands, tachycardic, and hypertensive, with hyperreflexia and ankle clonus.
Creatinine kinase rose to 613 units/L on hospital day 2. The toxicology service treated her with escalating doses of without improvement.
She was then intubated and sedated with a continuous propofol infusion. She was extubated after 2 days, all symptoms had resolved by day 3, and she was discharged home.
The second patient was a 59-year-old woman admitted for an omentectomy, during which she received IV fentaNYL 250 micrograms, etomidate, vecuronium, morphine, and cephazolin. After extubation she became hypoxic and acidotic and was reintubated and transferred to the ICU.
She was extubated on postoperative day 1 and later became tachycardic and unable to follow commands. On examination she was agitated and diaphoretic, with patellar hyperreflexia and bilateral ankle clonus of 3 to 4 beats.
Laboratory evaluation showed a peak creatine kinase of 1161 units/L on postoperative day 2. She was treated with LORazepam and cyproheptadine, and symptoms resolved after 3 days.7
-
Report 5 · Study title
Serotonin toxicity caused by an interaction between fentanyl and paroxetine
A case of postoperative after fentaNYL use for general anesthesia and postoperative analgesia was reported in a 60-year-old woman who was also receiving PARoxetine. Her outpatient medications were only PARoxetine and thyroxine, for depression and hypothyroidism.
She was admitted for extensive resection of a recurrent left chest wall myxofibrosarcoma and received propofol and 200 micrograms (mcg) of fentaNYL for anesthesia . She received a further 800 mcg of fentaNYL intraoperatively (intermittent 50 mcg boluses) and then a fentaNYL infusion (100 to 200 mcg/hr) for postoperative and analgesia (2545 mcg of fentanyl over 36 hours).
The infusion was continued for 36 hours postoperatively, at which point neurological examination showed intermittent agitation, bilateral hypertonia and hyperreflexia, and bilateral inducible ankle clonus. Symptoms were more severe in the lower limbs and on the right side of the body.
A CT scan of the brain was unremarkable, and all other findings, including thyroid function testing, were within normal limits except for elevated blood pressure (180/90 mmHg), which resolved spontaneously 24 hours after the procedure. fentaNYL was discontinued, and 24 hours later neurological symptoms had improved markedly, with complete recovery by postoperative day 4. She was ultimately discharged home without further complications.8
-
Report 6 · Study title
Ritonavir's role in reducing fentanyl clearance and prolonging its half-life
Twelve healthy volunteers received either placebo or oral ritonavir 3 times daily for 3 days, and fentaNYL 5 mcg/kg IV was given after the second ritonavir dose on day 2. Naloxone was given before and together with the fentaNYL dose to prevent its sedative and respiratory depressant effects.
One subject withdrew from the study before receiving fentaNYL. Among the 11 remaining participants, ritonavir reduced the plasma of fentaNYL by 67% (from 15.6 to 5.2 mL/min/kg).
Compared with placebo, the of fentaNYL increased from 9.4 hours to 20.1 hours after ritonavir, and the area under the concentration-time curve () rose by 174% (from 6.6 to 18.1 ng/mL/hr). Ritonavir is considered likely to affect the elimination of transdermally administered fentaNYL in a similar way.9
-
Report 7 · Study title
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
In an open, randomized, crossover study, of fluconazole with a single IV dose of fentaNYL reduced the mean plasma of fentaNYL by 16%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg either alone (control phase) or 1 hour after the final fluconazole dose on day 2 (400 mg orally once daily on day 1, then 200 mg orally once daily on day 2).
Naloxone was given before and with the fentaNYL dose to prevent sedative and respiratory depressant effects. All 12 subjects completed the study.
In the fluconazole phase, mean plasma clearance was 16% lower than in the control phase (range, -34% to 53%; p less than 0.05). The fentaNYL increased nonsignificantly (fluconazole phase, 7.7 +/- 2.3 nanograms (ng) x hr/mL vs control phase 6.1 +/- 1.1 ng x hr/mL), while the inactive norfentanyl decreased notably (fluconazole phase, 0.8 +/- 0.7 ng x hr/mL vs control phase, 1.8 +/- 1.1 ng x hr/mL), and the norfentanyl to fentaNYL AUC ratio was significantly lower in the fluconazole phase than in the control phase (AUC ratio, 0.1 +/- 0.1 vs 0.3 +/- 0.2).
The mean of fentaNYL did not differ between phases. The altered fentaNYL clearance appeared to result from of -mediated N-dealkylation of fentaNYL to norfentanyl.10
-
Report 8 · Study title
Possible fluconazole-fentanyl interaction-a case report
A 46-year-old man receiving transdermal fentaNYL died after concurrent treatment with fluconazole. He had oral pain from radiation therapy for tonsillar cancer and was treated with a fentaNYL 100 mcg/hr transdermal patch.
Over the next 1.5 months the fentaNYL dose was increased to 150 mcg/hr. medications were morphine 10 mg orally once daily, diclofenac 50 mg orally 3 times daily, paracetamol 1000 mg orally 3 times daily, oxazepam 15 mg orally twice daily, zolpidem 5 mg orally nightly, nystatin (100,000 international units/mL) 4 times daily, metoclopramide 20 mg rectally 3 times daily, lidocaine oral spray, and lactulose.
Two weeks after the increase to fentaNYL 150 mcg/hr, he underwent percutaneous gastrostomy because of worsening dysphagia. Eight days later he developed an oral fungal infection and was started on oral fluconazole 50 mg/day.
Three days after that, he died in his sleep. Forensic analysis found a toxic fentaNYL concentration (0.017 mcg/g), high concentrations of fluconazole (2.4 mcg/g), lidocaine (1.6 mcg/g), and metoclopramide (0.15 mcg/g), and a therapeutic zolpidem concentration.
There were no signs of ethanol or drugs of abuse. The only pathological autopsy findings were pulmonary congestion and brain edema. There was no indication of intentional overdose, and the coroner concluded that the cause of death was and circulatory failure from fentaNYL intoxication.11
-
Report 9 · Study title
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl
In an open, randomized, crossover study, of voriconazole with a single IV dose of fentaNYL raised the mean of fentaNYL 1.4-fold and lowered the mean plasma by 23%. Twelve healthy volunteers received a single IV dose of fentaNYL 5 mcg/kg either alone (control phase) or 1 hour after the final voriconazole dose on day 2 (400 mg orally twice daily on day 1, then 200 mg orally twice daily on day 2).
Naloxone was given before and with the fentaNYL dose to prevent sedative and respiratory depressant effects. All 12 subjects completed the study.
Compared with the control phase, during the voriconazole phase the mean fentaNYL AUC (0 to infinity) was 1.4-fold higher (range, 0.81- to 2.04-fold) and the mean plasma clearance was 23% lower (range -22% to 48%). Notably, the mean fentaNYL at 12 hr in the voriconazole phase matched the level at 6 hr in the control phase.
The mean of fentaNYL likewise did not differ between phases. Nausea and vomiting were reported in 4 subjects during the voriconazole phase and in 2 subjects during the control phase. No additional naloxone doses were needed, and no other adverse events were reported.10
Fluoxetine and Fentanyl: Common Questions
How serious is the Fluoxetine and Fentanyl interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Fluoxetine and Fentanyl interaction managed?
Your care team can usually manage this by tailoring your treatment. Keep taking both medicines exactly as prescribed unless your prescriber tells you otherwise. Your fentanyl dose may need to be lowered and individualized until your response is stable, and your team may monitor you more closely for sleepiness and slowed breathing. Watch for symptoms such as agitation, sweating,… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "established". Well documented — supported by controlled studies or strong clinical data.
Ask About the Fluoxetine and Fentanyl Interaction
Ask in your own words about taking Fluoxetine and Fentanyl together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (11)
- Boyer EW & Shannon M: The serotonin syndrome. N Eng J Med 2005; 352(11):1112-1120. PubMed
- Product Information: Fentanyl citrate intravenous, intramuscular injection, fentanyl citrate intravenous, intramuscular injection. Rising Pharma Holdings, Inc. (per FDA), East Brunswick, NJ, 2025. DailyMed
- Product Information: ACTIQ® oral transmucosal lozenge, fentanyl citrate oral transmucosal lozenge. Teva Pharmaceuticals USA, Inc. (per FDA), Parsippany, NJ, 2025. DailyMed
- Product Information: FENTORA® buccal tablets, fentanyl citrate buccal tablets. Teva Pharmaceuticals USA Inc (per FDA), Parsippany, NJ, 2025.
- Rastogi R, Swarm RA, & Patel TA: Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology 2011; 115(6):1291-1298. PubMed
- Alkhatib AA, Peterson KA, & Tuteja AK: Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy. Dig Dis Sci 2010; 55(1):215-216. DOI
- Kirschner R & Donovan JW: Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med 2010; 38(4):477-480. PubMed
- Rang ST, Field J, & Irving C: Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth 2008; 55(8):521-525. DOI
- Olkkola KT, Palkama VJ, & Neuvonen PJ: Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999; 91:681-685. PubMed
- Saari TI, Laine K, Neuvonen M, et al: Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. Eur J Clin Pharmacol 2008; 64(1):25-30. DOI
- Hallberg P, Marten L, & Wadelius M: Possible fluconazole-fentanyl interaction-a case report. Eur J Clin Pharmacol 2006; 62(6):491-492. PubMed
Other Serious Interactions of Fluoxetine and Fentanyl
Also serious with Fentanyl
- IsocarboxazidContraindicated
- LevoketoconazoleContraindicated
- NaltrexoneContraindicated
- PhenelzineContraindicated
Also serious with Fluoxetine
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Fentanyl
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- KavaMajor
- WineMajor
- 1,4-butanediolMajor
- BeerMajor
- Gamma-hydroxybutyrate (GHB)Major
- + 222 more
With Fluoxetine
- GrapefruitMajor
- Activated CharcoalMajor
- American HelleboreMajor
- ArsenicMajor
- CesiumMajor
- EphedraMajor
- LithiumMajor
- Sida CordifoliaMajor
- + 156 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data. This interaction.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.